DXCM Net income
Net income at Dexcom rose to $836M in fiscal 2025, the highest in the 5 years reported, from $576M in 2024.
Net income attributable to the parent / common stockholders, as filed.
SOURCE: us-gaap:NetIncomeLoss · EDGAR CompanyFacts · CIK 1093557 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$836M
FY2024 $576M
HIGH$836M FY2025
LOW$217M FY2021
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Net income | Change |
|---|---|---|
| FY2025 | $836M | +$260M |
| FY2024 | $576M | +$35M |
| FY2023 | $542M | +$200M |
| FY2022 | $341M | +$124M |
| FY2021 | $217M | — |
More SAME DATA, OTHER VIEWS
Net income across coverage → · DXCM company view →
Revenue · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.